Clinical trial
Venetoclax Combined With HAG Regimen in Treating Adult Relapse/Refractory Acute T Cell Lymphoblastic Leukemia/Lymphoma: A Phase II, Single Arm and Multicenter Study
NCT06742463 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Venetoclax Combined With HAG Regimen in Treating Adult Relapse/Refractory Acute T Cell Lymphoblastic Leukemia/Lymphoma: A Phase II, Single Arm and Multicenter Study
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 31, 2024
- Completion date
- June 30, 2028
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute t lymphpblastic leukemia/lymphoma